Below is a detailed analysis of the quarterly data for Everest Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 40.93 Cr.. The value appears to be declining and may need further review. It has decreased from 42.05 Cr. (Dec 2024) to 40.93 Cr., marking a decrease of 1.12 Cr..
For Expenses, as of Mar 2025, the value is 37.49 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.03 Cr. (Dec 2024) to 37.49 Cr., marking a decrease of 0.54 Cr..
For Operating Profit, as of Mar 2025, the value is 3.44 Cr.. The value appears to be declining and may need further review. It has decreased from 4.02 Cr. (Dec 2024) to 3.44 Cr., marking a decrease of 0.58 Cr..
For OPM %, as of Mar 2025, the value is 8.40%. The value appears to be declining and may need further review. It has decreased from 9.56% (Dec 2024) to 8.40%, marking a decrease of 1.16%.
For Other Income, as of Mar 2025, the value is 0.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.22 Cr., marking an increase of 0.22 Cr..
For Interest, as of Mar 2025, the value is 1.15 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.40 Cr. (Dec 2024) to 1.15 Cr., marking a decrease of 0.25 Cr..
For Depreciation, as of Mar 2025, the value is 1.56 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.47 Cr. (Dec 2024) to 1.56 Cr., marking an increase of 0.09 Cr..
For Profit before tax, as of Mar 2025, the value is 0.95 Cr.. The value appears to be declining and may need further review. It has decreased from 1.15 Cr. (Dec 2024) to 0.95 Cr., marking a decrease of 0.20 Cr..
For Tax %, as of Mar 2025, the value is -206.32%. The value appears to be improving (decreasing) as expected. It has decreased from 0.87% (Dec 2024) to -206.32%, marking a decrease of 207.19%.
For Net Profit, as of Mar 2025, the value is 2.91 Cr.. The value appears strong and on an upward trend. It has increased from 1.14 Cr. (Dec 2024) to 2.91 Cr., marking an increase of 1.77 Cr..
For EPS in Rs, as of Mar 2025, the value is 3.00. The value appears strong and on an upward trend. It has increased from 1.42 (Dec 2024) to 3.00, marking an increase of 1.58.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:31 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
96
106
99
107
112
156
167
182
200
183
197
159
Expenses
91
98
94
101
105
138
148
159
194
182
186
152
Operating Profit
5
8
6
6
7
18
19
23
6
1
11
7
OPM %
6%
7%
6%
6%
6%
11%
12%
13%
3%
1%
6%
5%
Other Income
1
-0
-0
1
1
1
1
1
2
7
1
1
Interest
3
3
3
3
3
3
3
3
3
3
5
5
Depreciation
2
3
3
2
3
3
3
3
4
4
6
6
Profit before tax
1
2
0
2
2
12
14
17
2
0
1
-3
Tax %
21%
20%
18%
24%
28%
39%
23%
21%
34%
311%
77%
-60%
Net Profit
1
2
0
1
2
8
11
14
1
-0
0
-1
EPS in Rs
0.54
1.69
2.14
9.39
13.62
17.15
1.42
-0.22
0.18
-1.33
Dividend Payout %
0%
0%
0%
0%
0%
11%
7%
9%
0%
0%
0%
0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2014-2015
2015-2016
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
YoY Net Profit Growth (%)
100.00%
-100.00%
100.00%
300.00%
37.50%
27.27%
-92.86%
-100.00%
Change in YoY Net Profit Growth (%)
0.00%
-200.00%
200.00%
200.00%
-262.50%
-10.23%
-120.13%
-7.14%
Everest Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2014-2015 to 2022-2023.
Growth
Compounded Sales Growth
10 Years:
4%
5 Years:
-1%
3 Years:
-7%
TTM:
-19%
Compounded Profit Growth
10 Years:
%
5 Years:
%
3 Years:
%
TTM:
-1021%
Stock Price CAGR
10 Years:
%
5 Years:
15%
3 Years:
35%
1 Year:
161%
Return on Equity
10 Years:
11%
5 Years:
6%
3 Years:
-1%
Last Year:
-2%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
1
4
7
10
5
9
10
14
14
18
16
-5
Cash from Investing Activity +
-3
-3
-7
-8
-4
-5
-6
-12
-17
-16
-13
-5
Cash from Financing Activity +
2
-2
-0
-2
-1
-3
-3
-2
2
-3
-3
16
Net Cash Flow
0
-0
0
0
-0
1
0
-0
-1
0
0
6
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
91
106
100
117
105
124
95
97
102
125
152
185
Inventory Days
55
46
44
55
73
72
71
102
110
110
139
128
Days Payable
164
184
184
235
260
251
190
211
183
212
282
324
Cash Conversion Cycle
-18
-32
-40
-63
-83
-55
-24
-12
29
24
9
-11
Working Capital Days
-22
8
7
6
-15
7
18
30
55
59
67
60
ROCE %
15%
13%
19%
11%
13%
13%
35%
35%
34%
6%
4%
6%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Promoters
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
74.15%
DIIs
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
Public
25.82%
25.82%
25.82%
25.82%
25.82%
25.82%
25.83%
25.83%
25.82%
25.82%
25.83%
25.83%
No. of Shareholders
10,784
11,135
11,154
11,244
11,250
11,100
10,834
10,634
10,494
10,242
10,023
9,792
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
-2.97
0.17
-0.23
1.43
17.14
Diluted EPS (Rs.)
-2.97
0.17
-0.23
1.43
17.14
Cash EPS (Rs.)
4.81
7.42
5.36
6.17
21.36
Book Value[Excl.RevalReserv]/Share (Rs.)
72.03
57.30
57.77
58.50
58.22
Book Value[Incl.RevalReserv]/Share (Rs.)
72.03
57.30
57.77
58.50
58.22
Dividend / Share (Rs.)
0.00
0.00
0.00
0.50
1.50
Revenue From Operations / Share (Rs.)
164.23
246.55
228.81
250.06
226.96
PBDIT / Share (Rs.)
8.14
14.84
9.84
10.80
29.88
PBIT / Share (Rs.)
2.00
7.60
4.25
6.05
25.66
PBT / Share (Rs.)
-3.34
0.76
0.11
2.17
21.59
Net Profit / Share (Rs.)
-1.33
0.17
-0.22
1.43
17.14
PBDIT Margin (%)
4.95
6.01
4.30
4.31
13.16
PBIT Margin (%)
1.22
3.08
1.85
2.42
11.30
PBT Margin (%)
-2.03
0.30
0.04
0.86
9.51
Net Profit Margin (%)
-0.80
0.07
-0.09
0.57
7.55
Return on Networth / Equity (%)
-1.84
0.30
-0.39
2.44
29.44
Return on Capital Employeed (%)
2.30
9.12
5.28
7.39
35.38
Return On Assets (%)
-0.57
0.06
-0.09
0.64
10.13
Long Term Debt / Equity (X)
0.13
0.31
0.25
0.23
0.12
Total Debt / Equity (X)
0.68
1.26
1.10
0.82
0.42
Asset Turnover Ratio (%)
0.70
0.92
0.96
1.28
1.42
Current Ratio (X)
1.06
0.93
0.96
1.05
1.15
Quick Ratio (X)
0.73
0.66
0.62
0.67
0.72
Inventory Turnover Ratio (X)
2.19
2.73
2.83
3.77
3.85
Dividend Payout Ratio (NP) (%)
0.00
0.00
-219.53
69.94
8.74
Dividend Payout Ratio (CP) (%)
0.00
0.00
9.32
16.19
7.02
Earning Retention Ratio (%)
0.00
0.00
319.53
30.06
91.26
Cash Earning Retention Ratio (%)
0.00
0.00
90.68
83.81
92.98
Interest Coverage Ratio (X)
1.52
2.17
2.38
2.78
7.34
Interest Coverage Ratio (Post Tax) (X)
0.75
1.03
0.94
1.37
5.21
Enterprise Value (Cr.)
285.94
148.80
126.35
177.17
202.22
EV / Net Operating Revenue (X)
1.79
0.75
0.69
0.88
1.11
EV / EBITDA (X)
36.15
12.53
16.05
20.51
8.46
MarketCap / Net Operating Revenue (X)
1.53
0.46
0.41
0.69
1.01
Retention Ratios (%)
0.00
0.00
319.53
30.05
91.25
Price / BV (X)
3.50
2.00
1.65
2.97
3.95
Price / Net Operating Revenue (X)
1.53
0.46
0.41
0.69
1.01
EarningsYield
-0.01
0.00
0.00
0.01
0.07
After reviewing the key financial ratios for Everest Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
For Diluted EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.42 (Mar 24) to 4.81, marking a decrease of 2.61.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.23. It has decreased from 246.55 (Mar 24) to 164.23, marking a decrease of 82.32.
For PBDIT / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has decreased from 14.84 (Mar 24) to 8.14, marking a decrease of 6.70.
For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 7.60 (Mar 24) to 2.00, marking a decrease of 5.60.
For PBT / Share (Rs.), as of Mar 25, the value is -3.34. This value is below the healthy minimum of 0. It has decreased from 0.76 (Mar 24) to -3.34, marking a decrease of 4.10.
For Net Profit / Share (Rs.), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 2. It has decreased from 0.17 (Mar 24) to -1.33, marking a decrease of 1.50.
For PBDIT Margin (%), as of Mar 25, the value is 4.95. This value is below the healthy minimum of 10. It has decreased from 6.01 (Mar 24) to 4.95, marking a decrease of 1.06.
For PBIT Margin (%), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 1.22, marking a decrease of 1.86.
For PBT Margin (%), as of Mar 25, the value is -2.03. This value is below the healthy minimum of 10. It has decreased from 0.30 (Mar 24) to -2.03, marking a decrease of 2.33.
For Net Profit Margin (%), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to -0.80, marking a decrease of 0.87.
For Return on Networth / Equity (%), as of Mar 25, the value is -1.84. This value is below the healthy minimum of 15. It has decreased from 0.30 (Mar 24) to -1.84, marking a decrease of 2.14.
For Return on Capital Employeed (%), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 10. It has decreased from 9.12 (Mar 24) to 2.30, marking a decrease of 6.82.
For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to -0.57, marking a decrease of 0.63.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.31 (Mar 24) to 0.13, marking a decrease of 0.18.
For Total Debt / Equity (X), as of Mar 25, the value is 0.68. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 0.68, marking a decrease of 0.58.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. It has decreased from 0.92 (Mar 24) to 0.70, marking a decrease of 0.22.
For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has increased from 0.93 (Mar 24) to 1.06, marking an increase of 0.13.
For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.73, marking an increase of 0.07.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 4. It has decreased from 2.73 (Mar 24) to 2.19, marking a decrease of 0.54.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 1.52, marking a decrease of 0.65.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 3. It has decreased from 1.03 (Mar 24) to 0.75, marking a decrease of 0.28.
For Enterprise Value (Cr.), as of Mar 25, the value is 285.94. It has increased from 148.80 (Mar 24) to 285.94, marking an increase of 137.14.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.79, marking an increase of 1.04.
For EV / EBITDA (X), as of Mar 25, the value is 36.15. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 36.15, marking an increase of 23.62.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Price / BV (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 24) to 3.50, marking an increase of 1.50.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Everest Organics Ltd as of June 26, 2025 is: 19.65
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Everest Organics Ltd is Overvalued by 94.56% compared to the current share price 361.00
Default values used*: Default value of 15 for Stock P/E is used
Intrinsic Value of Everest Organics Ltd as of June 26, 2025 is: 10.85
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Everest Organics Ltd is Overvalued by 96.99% compared to the current share price 361.00
Default values used*: Default value of 15 for Stock P/E is used
Last 5 Year EPS CAGR: -44.78%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Everest Organics Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: -1.84% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 0 (Industry average Stock P/E: 103.22)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.68
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Everest Organics Ltd. is a Public Limited Listed company incorporated on 19/02/1993 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1993PLC015426 and registration number is 015426. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 159.48 Cr. and Equity Capital is Rs. 9.71 Cr. for the Year ended 31/03/2025.
INDUSTRY
ADDRESS
CONTACT
Pharmaceuticals
Aroor Village, Sadasivpet Mandal, Sangareddy Dist. Telangana 502291
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Everest Organics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
